slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 77,161-77,190
Pages 3,679
Rows per page 30
Component
77,161-77,190 of 110,355
18
The slide uses a before-and-after experimental setup with microscopy images and longitudinal data plots to illustrate therapeutic resistance.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
19
The slide uses two distinct experimental examples (sequential vs combination inhibition) to illustrate the mechanism of resistance via ecDNA.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
26
The slide uses a comparative visual framework to contrast normal vs. stressed replication mechanisms.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank Beat · Solution (Provide relief)1 hit
30
Includes a mechanism of action diagram illustrating 'Therapy Enhanced Synthetic Lethality'.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
33
The slide highlights the 60mg dose as the MTD (Maximum Tolerated Dose) and shows it crosses the threshold for tumor regression.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
34
The table uses a grid layout to show AE frequency across different dosage cohorts (20mg, 40mg, 60mg, 80mg Q2D, 80mg 2ON/5OFF, 120mg 2ON/5OFF).Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
36
The slide uses a Gantt-style timeline to map trial phases against calendar years.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
38
The slide uses a table structure to map initial drivers to resistance mechanisms, supported by clinical citations and microscopy images.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
39
The slide uses a biological mechanism diagram to explain the therapeutic rationale for BBI-825.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
43
The slide uses a 'STARMAP' acronym to describe the study design.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
46
The slide uses two pie charts to represent patient populations and a central circular diagram to illustrate the biological nodes (Replication Stress, Assembly & Repair, Segregation).Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank Beat · Market SizeLoop · Golden Circle1 hit
51
The table uses a clear contrast-based layout to differentiate the two lead molecules.Boundless Bio | IPO Presentation Deck | 51 slides · Boundless Bio
Pitch deck Investment bank 1 hit
05
The slide uses a chevron-based layout to categorize key company pillars.CARGO Therapeutics | IPO Presentation Deck | 29 slides · CARGO Therapeutics
Pitch deck Investment bank Loop · Golden Circle1 hit
08
The chart uses a Gantt-style visualization to represent clinical trial phases for different indications.CARGO Therapeutics | IPO Presentation Deck | 29 slides · CARGO Therapeutics
Pitch deck Investment bank Loop · Golden Circle1 hit
09
CARGO Therapeutics | IPO Presentation Deck | 29 slidesCARGO Therapeutics | IPO Presentation Deck | 29 slides · CARGO Therapeutics
Pitch deck Investment bank Beat · Market SizeLoop · Golden Circle1 hit
10
The slide uses a Kaplan-Meier curve to visually demonstrate the 'problem' (rapid progression) and a callout box to quantify the market opportunity.CARGO Therapeutics | IPO Presentation Deck | 29 slides · CARGO Therapeutics
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
12
Includes Kaplan-Meier survival curves and a summary table of clinical outcomes.CARGO Therapeutics | IPO Presentation Deck | 29 slides · CARGO Therapeutics
Pitch deck Investment bank Beat · TractionLoop · Cost Of Inaction1 hit
13
The slide uses a process flow diagram to illustrate the clinical trial stages.CARGO Therapeutics | IPO Presentation Deck | 29 slides · CARGO Therapeutics
Pitch deck Investment bank Beat · TractionLoop · Cost Of Inaction1 hit
14
The slide uses a comparison table to contrast clinical trial data for CRG-022 against historical benchmarks for ZUMA-1, JULIET, and TRANSCEND.CARGO Therapeutics | IPO Presentation Deck | 29 slides · CARGO Therapeutics
Pitch deck Investment bank Beat · TractionLoop · Cost Of Inaction1 hit
15
Kaplan-Meier survival curve shown.CARGO Therapeutics | IPO Presentation Deck | 29 slides · CARGO Therapeutics
Pitch deck Investment bank Beat · TractionLoop · Cost Of Inaction1 hit
18
The slide uses a biological schematic to explain the mechanism of action and key design features of the therapeutic candidate.CARGO Therapeutics | IPO Presentation Deck | 29 slides · CARGO Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
21
The slide uses a biological mechanism diagram, a Kaplan-Meier survival curve, and IHC images to demonstrate the clinical impact of CD58 loss.CARGO Therapeutics | IPO Presentation Deck | 29 slides · CARGO Therapeutics
Pitch deck Investment bank Loop · Golden Circle1 hit
07
Uses a comparative diagram to illustrate the biological mechanism.CG Oncology | IPO Presentation Deck | 45 slides · CG Oncology
Pitch deck Investment bank Beat · Solution1 hit
08
The slide uses a circular process diagram overlaid on a cross-section of a bladder to explain the treatment steps.CG Oncology | IPO Presentation Deck | 45 slides · CG Oncology
Pitch deck Investment bank Beat · Solution1 hit
09
Uses a before-after framing to explain the mechanism of action for the DDM surfactant.CG Oncology | IPO Presentation Deck | 45 slides · CG Oncology
Pitch deck Investment bank Beat · Solution1 hit
11
The slide uses a three-column layout to categorize the problem into prevalence, clinical challenges, and patient profile.CG Oncology | IPO Presentation Deck | 45 slides · CG Oncology
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
12
The diagram shows the progression of tumor invasion through the bladder wall layers (Lamina Propria, Inner Muscle, Deep Muscle).CG Oncology | IPO Presentation Deck | 45 slides · CG Oncology
Pitch deck Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
13
The slide uses a process flow that transitions into a decision tree/matrix based on risk levels.CG Oncology | IPO Presentation Deck | 45 slides · CG Oncology
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
16
Includes FDA Fast Track and Breakthrough Therapy designations.CG Oncology | IPO Presentation Deck | 45 slides · CG Oncology
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
20
BOND-003 clinical trial safety data.CG Oncology | IPO Presentation Deck | 45 slides · CG Oncology
Pitch deck Investment bank Loop · Cost Of Inaction1 hit